You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
McKinsey
Baxter
AstraZeneca
Merck

Last Updated: September 20, 2020

DrugPatentWatch Database Preview

Patent: 8,956,611

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,956,611
Title:Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease
Abstract: The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and anti-CD20 agents for the treatment of autoimmune diseases. One preferred method is where the BLyS antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF--R-Fc-fusion protein comprising the extracellular domain of BAFF--R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of anti-CD20 agents contemplated include RITUXAN.RTM., (rituximab),ocrelizumab, ofatumumab (HuMax-CD20.RTM.), TRU-015, and DXL625, although any agent that binds to CD 20 may be suitable. The methods of the present invention reduce the levels of B cells in patients in need of such reduction, such as those suffering from autoimmune diseases.
Inventor(s): Ponce, Jr.; Rafael A. (Seattle, WA), Peano; Sergio (Ivrea, IT), Broly; Herve (Saint Selve, FR), Graffner; Hans Otto Lennart (Helsingborg, SE)
Assignee: ZymoGenetics, Inc. (Seattle, WA) Ares Trading S.A. (Aubonne, CH)
Application Number:12/252,955
Patent Claims:see list of patent claims

Details for Patent 8,956,611

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial ZymoGenetics, Inc. (Seattle, WA) Ares Trading S.A. (Aubonne, CH) 2027-10-16 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial ZymoGenetics, Inc. (Seattle, WA) Ares Trading S.A. (Aubonne, CH) 2027-10-16 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial ZymoGenetics, Inc. (Seattle, WA) Ares Trading S.A. (Aubonne, CH) 2027-10-16 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial ZymoGenetics, Inc. (Seattle, WA) Ares Trading S.A. (Aubonne, CH) 2027-10-16 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Colorcon
Boehringer Ingelheim
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.